reatment decisions, including prescription of drugs, for patients increasingly rely on evidence obtained by clinical trials conducted under well-designed protocols and reliable controlled procedures rather than on unsystematic clinical experience. The concept of evidencebased medicine (EBM) has become very popular and the results of large-scale clinical intervention trials are having greater influence on daily clinical activities. According to the Agency for Health Care Policy and Research, evidence from meta-analyses of randomized controlled trials (RCTs) is of the highest level, with that from ≥1 RCTs classed as the next most compelling. 1 From protocol development until data analysis, however, RCTs require long time periods and incur great costs, which are further increased when meta-analyses of several RCTs are required.
or influenced by drug manufacturers. In addition, even if a clinician goes through each original article and acquires a grasp of the key points, selection of the best medication based on the results of various trials is still not easy. Therefore, in the present study an attempt has been made to compare the strength of scientific evidence obtained from largescale clinical trials evaluating different drugs in the same class, using angiotensin-receptor blockers (ARBs) in this instance. ARBs are some of the most attractive antihypertensive drugs because their use and reports of their benefits have increased since the start of their clinical application worldwide, including in Japan. [2] [3] [4] [5] The author has avoided the use of difficult statistical techniques and developed an "evidence score (ES)" system that enables simple comparison of the strength of evidence obtained from large-scale clinical intervention trials. This report provides an explanation of ES and its application.
Proposed New Score to Rate the Strength of Evidence and Its Application to Large-Scale Clinical Trials of Angiotensin-Receptor Blockers
Tsutomu Yamazaki, MD
Background Many large-scale clinical studies appear to be interpreted with bias and with hindsight. To select the best treatment, accurate evaluation of randomized controlled trials (RCTs) and fair comparison of the results using the concept of evidence-based medicine are critical. A scoring system has been developed to rate the scientific strength of evidence and thereby provide guidance for best clinical practice and for large-scale RCTs of angiotensin-receptor blockers (ARBs).
Method and Results
Positive evidence scores (ESs) were given based on whether specified study endpoints were proven and whether treatments tested made significant progress over current usual therapy. Retrospective ad hoc analyses data were not counted, in order to simplify the system and to avoid hindsight interpretations, even in cases that were medically significant. In fact, in more than half of the large-scale trials with ARBs examined, ad-hoc analyses had been retroactively performed. When such post-hoc analyses were not used, the ESs were positive with candesartan and valsartan for treatment of heart failure, irbesartan and losartan for nephropathy and losartan for hypertension. Applying the ES system, losartan was judged to be an ARB with the strongest evidence covering a wide range of clinical relevance. However, these 4 RCTs contributed 83 references, nearly one-fifth of the total number of references. ARBs tested in this study were limited to candesartan, irbesartan, losartan, and valsartan, because there are relatively few data for other ARBs published to date. All endpoints prospectively specified in the design papers were taken into account in the ES analyses. However, ad hoc analysis data were excluded to eliminate any doubts concerning hindsight findings ascertained through retrospective analyses of accumulated data. Although a search was conducted for reports citing similar scoring systems when setting down the provisions for the current ES system, no relevant reports were found. Consequently, the author has independently set down the provisions for this scoring system. Because the primary endpoint in any particular trial was deemed more important than secondary endpoints, a score of 4 was arbitrarily given if significant superiority was shown over placebo in the primary endpoint, and 1 point was similarly given for each secondary endpoint. If significant superiority was demonstrated over the active comparator regimen, which must be the standard treatment choice at the time, the scores were doubled as summarized in Table 1 . Strength of evidence was then compared among ARBs as total ES scores and as positive points scored by subcategory of cardiovascular disease and by organ protected such as brain, heart, and kidney.
Results
ES scores obtained from the results of RCTs including >1,000 patients are listed in Table 2 . Six studies (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM)-Alternative 6 and CHARMAdded 7 for candesartan, Irbesartan Type II Diabetic Nephropathy Trial (IDNT) 10 for irbesartan, LIFE 11 and RENAAL 13 for losartan, and Valsartan Heart Failure Trial (Val-HeFT) 17 for valsartan) achieved positive results in the predefined endpoints. Losartan gained the highest score/ study in LIFE 11 and in total points. In the subcategories, only losartan achieved a positive ES in hypertensive patients (Table 3) . 11 Although several trials of candesartan and valsartan were conducted in this population, clinical advantage was not clearly demonstrated in primary and other endpoints and thus the ES scores were zero in hypertensive patients. 9, 15 In studies in heart failure patients, however, losartan scored zero, 14 whereas both candesartan 6,7 and valsartan 17 gave positive scores. In diabetic nephropathy patients, both irbesartan 10 and losartan 13 proved positive. In patients with myocardial infarction, no positive ES scores were obtained in trials of losartan 12 and valsartan. 16 No data on sufficient number of patients are available for candesar- Tables 2,3. tan or irbesartan in this category. Table 4 shows the ES scores of ARBs by end organ, new onset of diabetes, and composite endpoint covering multiple factors. Losartan achieved positive scores for protecting brain, heart, and kidney, reducing new onset of diabetes, and showing clinical benefit in composite primary endpoints in LIFE 11 and against fatal and nonfatal cardiovascular and renal events in RENAAL, 13 whereas candesartan achieved a positive score only in cardioprotection; the score was zero for brain and the composite endpoint fatal and nonfatal cardiovascular events. 6, 7 Valsartan showed positive evidence only in Val-HeFT 17 for heart and the composite endpoint regarding all-cause mortality and cardiovascular morbidity. Irbesartan proved positive in the composite primary endpoint covering renal function and all-cause mortality, whereas the results were negative in the secondary composite endpoint of fatal and nonfatal cardiovascular events. 20 Discussion EBM, proposed in 1992, 28 is defined as the process by which execution of medical judgment is based on systematic evaluation of reliable medical evidence. In this study, an ES system was devised to provide a simple method of rating the strength of medical evidence and applying it to large-scale clinical trials of ARBs. The results of the ES analyses suggest that the ARB with the highest degree of evidence favorable for treating cardiovascular diseases and for end-organ protection is losartan. However, the ES is arbitrary in this method. To test the validity, an alternative method was tried, in which the score was given as 1, 2, 3, 4, respectively. Losartan scored 14, candesartan 11, valsartan 6, irbesartan 4 and the order of efficacy did not change.
Futhermore, even if the score of -1 was given as negative evidence, the resulting order is the same as the above.
Of 12 clinical trials 6 scored zero in the ES system. The score of zero in the ES does not mean that the treatment choice is inefficacious, but suggests that the choice may not provide significant advances over the standard medication. In clinical trials, investigators usually test 1 major hypothesis as the primary endpoint and several related assumptions as secondary endpoints. Although the setting of multiple endpoints increases the probability of obtaining coincidental significant differences, multiple clinical endpoints have the advantage of addressing specific medical questions efficiently because clinical trials require huge costs and considerable labor and time. Consequently, the most efficient method is to establish multiple hypotheses to be tested in the trial and to designate one of particular importance as the primary endpoint. Recently, the International Committee of Medical Journal Editors (ICMJE) announced that, in relation to clinical trials scheduled to begin after July 1, 2005, preregistration would be a requisite condition for publication in the main ICMJE member medical journals. 29 This would serve to alleviate concerns regarding publication of results showing only positive data with no negative data presented or reporting retroactive hindsight interpretations and to maintain transparency. Although the results of the MOSES Study were reported recently, 30 a design paper for this trial has not been published as yet. MOSES was therefore omitted from the ES analysis.
When the design papers were compared with the articles reporting the results, about half of the endpoints stipulated in the former were ignored or modified in the latter. Although none of these cases concern the primary endpoints, there was a report in which composite endpoints were shown in the results, even though separate independent endpoints had been set in the design paper, as well as cases where the endpoints reported had not been mentioned at all in the design papers. Reduction of new onset of diabetes fell into the latter category in the CHARM-Preserved 8, 18 and Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trials, 15, 16 whereas this endpoint had been clearly stated only in the LIFE design paper 21 in advance. 11 The objective of clinical trials should be to verify stated hypotheses, and it is important to note that even the outcomes of trials that are believed to provide excellent medical evidence are questionable from the ES verification.
A simple scoring system to rate the strength of clinical evidence is proposed here. However, the system should be further investigated and refined. For future improvements, several points should be considered. In a trial studying heart failure prognosis, the primary endpoint for ELITE II 14 was all-cause mortality, whereas for CHARM 6-8 a composite primary endpoint was given as cardiovascular mortality or admission to hospital due to heart failure, and in Val-HeFT 17 2 primary endpoints, all-cause mortality and cardiovascular events including all-cause mortality, were placed. Obviously, incidence of all-cause mortality is lower in comparison to that of cardiovascular events and admission to hospital due to heart failure, and it would be more difficult to achieve a statistically significant difference from the control arm. In addition, of the 12 trials analyzed in this study, only Val-HeFT 17 had 2 primary endpoints, and as such, the possibility of obtaining advantageous results could be higher. It would be better to unify primary endpoints and establish guidelines for protocol designing for future clinical trials for diseases such as heart failure. To interpret the results accurately, the doses of ARBs used in such trials may also require attention. The maximal dose for losartan used in LIFE 11 and RENAAL, 13 which resulted in positive ES, was 100 mg/day, whereas that in OPTIMAAL 12 and ELITE II, 14 which gave zero ES, was 50 mg/day. The maximal doses used for candesartan were 32 mg/day in the 3 CHARM trials 6-8 and 16 mg/day in Study on Cognition and Prognosis in the Elderly, 9 and those for valsartan were 320 mg/day in Valsartan in Acute Myocardial Infarction Trial 16 and Val-HeFT 17 and 160 mg/day in VALUE. 15 All positive ES scores were obtained in those trials using higher doses, suggesting that high clinical doses of ARBs might be one of the key factors for their clinical success. The irbesartan dose used in IDNT 10 was ≤300 mg/day. Although the biological characteristics of the active comparator might slightly affect the results, they were not taken into consideration in the ES to maintain simplicity and ease of application.
In this study, ES scores were arbitrarily set to quantify and compare the strength of evidence obtained in largescale RCTs of ARBs. The author intends to further improve the ES system from various aspects to develop a more refined scoring system.
